VCYT

Veracyte

• Seeking Alpha·2d ago

  Cathie Wood's weekly moves signal shift to AI, precision medicine

• Dow Jones·04/01 11:52

  Veracyte Is Maintained at Buy by Needham

• Dow Jones·04/01 11:52

  Veracyte Price Target Maintained With a $48.00/Share by Needham

• Benzinga·04/01 11:42

  Needham Maintains Buy on Veracyte, Maintains $48 Price Target

• TipRanks·04/01 09:45

  Veracyte: Leveraging TrueMRD and Decipher Bladder to Capture a $200M Minimal Residual Disease Opportunity

• Seeking Alpha·03/31 10:35

  Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names

• Dow Jones·03/30 15:11

  Veracyte Is Maintained at Buy by Guggenheim

• Dow Jones·03/30 15:11

  Veracyte Price Target Cut to $45.00/Share From $50.00 by Guggenheim

• Benzinga·03/30 15:01

  Guggenheim Maintains Buy on Veracyte, Lowers Price Target to $45

• TipRanks·03/30 11:52

  Veracyte price target lowered to $45 from $50 at Guggenheim

• NASDAQ·03/27 15:30

  Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?

• Reuters·03/25 20:51

  Veracyte files initial beneficial ownership statement; Chief Dev and Tech Officer Kevin Richard Haas reports no securities beneficially owned

• TipRanks·03/16 20:57

  Veracyte Appoints Kevin Haas as Chief Technology Leader

• TipRanks·03/16 20:26

  Veracyte names Kevin Haas as Chief Development and Technology Officer

• Reuters·03/16 20:15

  Veracyte appoints Kevin Haas as chief development and technology officer